• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Dynatronics Corporation Reports Second Quarter Fiscal Year 2023 Financial Results and Business Highlights

    2/9/23 7:30:00 AM ET
    $DYNT
    Medical/Dental Instruments
    Health Care
    Get the next $DYNT alert in real time by email

    EAGAN, MN / ACCESSWIRE / February 9, 2023 / Dynatronics Corporation (NASDAQ:DYNT) ("Dynatronics" or the "Company"), a manufacturer of athletic training, physical therapy, and rehabilitation products, today reported financial results for its second quarter of fiscal year 2023 ended December 31, 2022, and provided an update on the business.

    CEO Commentary

    "The year-over-year improvement in gross margin of 8.4% or nearly $1.0 million in gross profit was a solid improvement. We are pleased with our progression, but we have more work to do. New, targeted, and innovative, product releases are the third pillar of our gross margin improvement plan, and we plan to continue to improve our performance in this area," said John Krier, Chief Executive Officer of Dynatronics.

    "Our inventory balance was reduced to $10.7 million with a reduction of approximately $1.4 million from the balance on June 30, 2022. Reducing inventory by this level, allowed us to strengthen our supplier relationships with a reduction in accounts payable of approximately $0.9 million in the second quarter. This is an important development as we work to optimize our inventory with selected reductions while preparing for future new product introductions and historical seasonality-related growth expected in our fiscal fourth quarter," concluded Krier.

    Key Financial Highlights

    Q2 Fiscal Year ‘23 Financial Highlights

    Note: All financials referenced in this release are in conformity with U.S. Generally Accepted Accounting Principles ("GAAP") and comparisons in this release are to the same period in the prior year unless otherwise noted.

    • Total net sales of $10.9 million.
    • Gross profit margin of 28.1% up from 19.8% in Q2 fiscal year ‘22.
    • Net loss of $0.8 million improved from $1.4 million in Q2 fiscal year ‘22.
    • Current liabilities reduced by $1.0 million in Q2 fiscal year ‘22.
    • Cash of $0.7 million, flat from $0.7 million at the end of Q4 fiscal year ‘22.
    • 10th consecutive quarter of no debt.

    Guidance for Fiscal Year ‘23

    Dynatronics reaffirmed net sales guidance for fiscal year ‘23 of $45 million to $48 million. The midpoint of this range is a 5% improvement over the Company's $44.3 million net sales in fiscal year ‘22. The Company expects the distribution of net sales across the quarters in fiscal year ‘23 to align with historical trends, which are highest in the first quarter, lower in the second and third quarters, with a bounce back in the fourth quarter. The second quarter of fiscal year 2023 continued this historical seasonality trend.

    Even as it expects fiscal year '23 to showcase continued improvement toward its 40% long-term goal, given the persistent inflationary pressure and macro-economic impacts the Company is deferring providing gross margin guidance.

    Selling, general, and administrative expenses are anticipated to be 30% to 35% of net sales in fiscal year ‘23.

    Dynatronics expects to continue its strategic approach to optimize inventory levels with selected reductions while preparing for future new product introductions and historical seasonality-related growth expected in our fiscal fourth quarter. This approach allowed the company to generate positive cash flow from operations of $0.3 million for the first six months of the fiscal year.

    The Company's financial guidance for fiscal year '23 is subject to the risks identified in its safe harbor notification below. The Company continues to expect volatility due to the challenges related to the broader economic environment and the COVID-19 global pandemic, including higher raw material, delivery and shipment costs, supply chain disruptions, extended handling times and delays or disruption in procedure volume. Dynatronics also expects some ongoing volatility from the Company's business optimization.

    Growth Priorities

    The Company has delivered sales growth that outpaced market growth, and its baseline continued product net sales expectation for the seventh consecutive quarter. Dynatronics employs multiple levers to drive sales growth - by capturing market share, product innovations, and through acquisitions.

    Conference Call and Webcast Q1 Fiscal Year ‘23 Results

    The Company will hold a conference call and live audio webcast to discuss the results, consisting of prepared remarks by management, slide presentation, and a question-and-answer session with analysts, beginning at 8:00 AM ET on Thursday, February 9, 2023.

    Interested persons may access the live conference call by dialing 888-506-0062 (U.S./Canada callers) or 973-528-0011 (international callers), using passcode 547446. It is recommended that participants call or log in 10 minutes ahead of the scheduled start time to ensure a proper connection. An audio replay will be available one hour after the live call until Midnight on February 16, 2023, by dialing 877-481-4010, using passcode 47501.

    The live webcast and slide presentation can be accessed on the Company's Investor webpage under the Events & Presentations tab at https://investors.dynatronics.com/services. The webcast will be archived on the website for future viewing.

    About Dynatronics Corporation

    Dynatronics is a leading medical device company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The Company designs, manufactures and sells a broad range of products for clinical use in physical therapy, rehabilitation, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and consumers. The Company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin®, Solaris™, Hausmann®, Physician's Choice®, and PROTEAM™, among others. More information is available at www.dynatronics.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Those statements include references to the Company's expectations and similar statements. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our statements regarding expected improvement in overall performance, expectations that the Company will improve long-term gross margins, operating income and cash flow from operations, expectations regarding net sales, gross margin, selling general and administrative costs, and other income in fiscal year 2023, and uncertainties related to the broader economic environment and the impact of the COVID-19 global pandemic on the Company's results of operations and financial condition. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in the Company's annual, quarterly, and other reports filed with the Securities and Exchange Commission.

    About Non-GAAP Financial Measures

    Continued product net sales as used in this press release is a non-GAAP measure as defined under the rules of the Securities and Exchange Commission. The Company defines continued product net sales as sales excluding discontinued products and sales of physical therapy and rehabilitation products through our direct sales channel. Management uses this non-GAAP measure to evaluate our operating performance and to forecast future periods. Management believes this non-GAAP measure provides investors with additional information about the Company's ongoing operating performance and is not intended as a substitute for, or superior to, the financial measure prepared in accordance with GAAP. Investors are cautioned against placing undue reliance on this non-GAAP measure. $37 million annual and $9.25 million quarterly baseline continued product net sales set in April 2021 is based on annual net sales of approximately $48 million in FY '21 less estimated annual discontinued product sales of approximately $11 million.

    Summary Financial Results

    Following is a summary of operating results for the periods ended December 31, 2022, the balance sheet highlights at December 31, 2022 and cash flow for periods ended December 31, 2022.


    Dynatronics Corporation, Thursday, February 9, 2023, Press release picture

    Dynatronics Corporation, Thursday, February 9, 2023, Press release picture

    Dynatronics Corporation, Thursday, February 9, 2023, Press release picture

    Dynatronics Corporation, Thursday, February 9, 2023, Press release picture

    CONTACT:
    Dynatronics Corporation
    Investor Relations
    [email protected]

    For additional information, please visit: www.dynatronics.com

    Connect with Dynatronics on LinkedIn

    SOURCE: Dynatronics Corporation



    View source version on accesswire.com:
    https://www.accesswire.com/738727/Dynatronics-Corporation-Reports-Second-Quarter-Fiscal-Year-2023-Financial-Results-and-Business-Highlights

    Get the next $DYNT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DYNT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DYNT
    SEC Filings

    See more
    • SEC Form 10-Q filed by Dynatronics Corporation

      10-Q - DYNATRONICS CORP (0000720875) (Filer)

      5/12/25 4:00:27 PM ET
      $DYNT
      Medical/Dental Instruments
      Health Care
    • Dynatronics Corporation filed SEC Form 8-K: Leadership Update

      8-K - DYNATRONICS CORP (0000720875) (Filer)

      5/9/25 8:00:26 AM ET
      $DYNT
      Medical/Dental Instruments
      Health Care
    • Dynatronics Corporation filed SEC Form 8-K: Leadership Update

      8-K - DYNATRONICS CORP (0000720875) (Filer)

      4/18/25 7:30:18 AM ET
      $DYNT
      Medical/Dental Instruments
      Health Care

    $DYNT
    Financials

    Live finance-specific insights

    See more
    • Dynatronics Corporation Reports Third Quarter Fiscal Year 2023 Financial Results and Business Highlights

      Eagan, Minnesota--(Newsfile Corp. - May 11, 2023) - Dynatronics Corporation (NASDAQ:DYNT) ("Dynatronics" or the "Company"), a manufacturer of athletic training, physical therapy, and rehabilitation products, today reported financial results for its third quarter of fiscal year 2023 ended March 31, 2023, and provided an update on the business.CEO Commentary"Dynatronics experienced revenue challenges in our third fiscal quarter as a result of three external factors. As a result, we are adjusting our spending and revenue expectations as we respond to the specific impacts of:Competitive acquisitions by a significant rehabilitation customer; Reduction in specific SKUs of an OEM customer for the

      5/11/23 7:00:00 AM ET
      $DYNT
      Medical/Dental Instruments
      Health Care
    • Dynatronics Corporation Schedules Conference Call to Report Third Quarter Results for Fiscal 2023

      Eagan, Minnesota--(Newsfile Corp. - April 27, 2023) - Dynatronics Corporation (NASDAQ:DYNT), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today announced that the company will release financial results for its third quarter of fiscal year 2023 on Thursday, May 11, 2023 before the market opens.The company will subsequently hold a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session with analysts, at 8:00 AM ET on Thursday, May 11, 2023, to review its third quarter results.Interested persons may access the live conference call by dialing 1-800-319-4610 (U.S./Canada calle

      4/27/23 8:00:00 AM ET
      $DYNT
      Medical/Dental Instruments
      Health Care
    • Dynatronics Corporation Reports Second Quarter Fiscal Year 2023 Financial Results and Business Highlights

      EAGAN, MN / ACCESSWIRE / February 9, 2023 / Dynatronics Corporation (NASDAQ:DYNT) ("Dynatronics" or the "Company"), a manufacturer of athletic training, physical therapy, and rehabilitation products, today reported financial results for its second quarter of fiscal year 2023 ended December 31, 2022, and provided an update on the business.CEO Commentary"The year-over-year improvement in gross margin of 8.4% or nearly $1.0 million in gross profit was a solid improvement. We are pleased with our progression, but we have more work to do. New, targeted, and innovative, product releases are the third pillar of our gross margin improvement plan, and we plan to continue to improve our performance in

      2/9/23 7:30:00 AM ET
      $DYNT
      Medical/Dental Instruments
      Health Care

    $DYNT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Leixir Dental Laboratory Group Appoints John Krier as Chief Executive Officer

      Leixir Dental Laboratory Group (Leixir), a leading operator of a full-service, state-of-the-art dental laboratory network, today announced the appointment of John Krier as Chief Executive Officer, effective January 2nd, 2024. Mr. Krier succeeds Leixir founder Harmeet Bindra, who will continue as Executive Chairman. Mr. Krier brings nearly two decades of executive leadership experience in the medical device manufacturing and distribution industries. He joins Leixir from Dynatronics Corporation (NASDAQ:DYNT), where he was most recently President and CEO. Before that, he held senior roles in corporate strategy and commercial execution, including marketing and customer experience, over seven

      1/8/24 8:00:00 AM ET
      $DYNT
      Medical/Dental Instruments
      Health Care
    • Appointment of Dr. Christopher von Jako as new CEO

      Durham, N.C., June 21, 2023 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), the medical imaging company, announces that the Company's Board of Directors has appointed Christopher von Jako, Ph.D. ("Dr. von Jako") as Chief Executive Officer and director of the Company, effective immediately. Dr. von Jako succeeds Richard Hullihen, who will be retiring and will be stepping down as a Director of the Company, effective immediately. Mr. Hullihen will assist the Company in a transitional position for the next six months. Since his appointment as CEO in 2017, Richard has overseen significant progress for Polarean. He led the Company through its successful IPO in 2018 and over $60M of ca

      6/21/23 9:00:00 AM ET
      $DYNT
      Medical/Dental Instruments
      Health Care
    • Dynatronics Announces Planned Resignation of John Krier as CEO; Brian Baker Appointed President and CEO Successor After Transition

      Consistency of Executive Leadership Expected to Provide Smooth TransitionEagan, Minnesota--(Newsfile Corp. - May 18, 2023) - Dynatronics Corporation (NASDAQ:DYNT), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today announced that Chief Executive Officer and Director John Krier has informed the Board of his intention to resign from the company by the end of September 2023 to pursue other professional interests. Brian Baker, the company's current Chief Operating Officer, and former President and Chief Executive Officer, has accepted the role of President of Dynatronics effective immediately and will assume the titles of President, Chief Executive

      5/18/23 8:05:00 AM ET
      $DYNT
      Medical/Dental Instruments
      Health Care

    $DYNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Staats Ryan Edward claimed ownership of 40 shares (SEC Form 3)

      3 - DYNATRONICS CORP (0000720875) (Issuer)

      5/12/25 4:00:53 PM ET
      $DYNT
      Medical/Dental Instruments
      Health Care
    • Director Enright Erin S. acquired 739,014 shares (SEC Form 4)

      4 - DYNATRONICS CORP (0000720875) (Issuer)

      4/3/25 3:12:03 PM ET
      $DYNT
      Medical/Dental Instruments
      Health Care
    • Large owner Provco Ventures 1 Lp acquired 369,292 shares, increasing direct ownership by 29% to 1,633,439 units (SEC Form 4)

      4 - DYNATRONICS CORP (0000720875) (Issuer)

      4/3/25 3:10:57 PM ET
      $DYNT
      Medical/Dental Instruments
      Health Care

    $DYNT
    Leadership Updates

    Live Leadership Updates

    See more
    • Leixir Dental Laboratory Group Appoints John Krier as Chief Executive Officer

      Leixir Dental Laboratory Group (Leixir), a leading operator of a full-service, state-of-the-art dental laboratory network, today announced the appointment of John Krier as Chief Executive Officer, effective January 2nd, 2024. Mr. Krier succeeds Leixir founder Harmeet Bindra, who will continue as Executive Chairman. Mr. Krier brings nearly two decades of executive leadership experience in the medical device manufacturing and distribution industries. He joins Leixir from Dynatronics Corporation (NASDAQ:DYNT), where he was most recently President and CEO. Before that, he held senior roles in corporate strategy and commercial execution, including marketing and customer experience, over seven

      1/8/24 8:00:00 AM ET
      $DYNT
      Medical/Dental Instruments
      Health Care
    • Appointment of Dr. Christopher von Jako as new CEO

      Durham, N.C., June 21, 2023 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), the medical imaging company, announces that the Company's Board of Directors has appointed Christopher von Jako, Ph.D. ("Dr. von Jako") as Chief Executive Officer and director of the Company, effective immediately. Dr. von Jako succeeds Richard Hullihen, who will be retiring and will be stepping down as a Director of the Company, effective immediately. Mr. Hullihen will assist the Company in a transitional position for the next six months. Since his appointment as CEO in 2017, Richard has overseen significant progress for Polarean. He led the Company through its successful IPO in 2018 and over $60M of ca

      6/21/23 9:00:00 AM ET
      $DYNT
      Medical/Dental Instruments
      Health Care
    • Dynatronics Announces Planned Resignation of John Krier as CEO; Brian Baker Appointed President and CEO Successor After Transition

      Consistency of Executive Leadership Expected to Provide Smooth TransitionEagan, Minnesota--(Newsfile Corp. - May 18, 2023) - Dynatronics Corporation (NASDAQ:DYNT), a leading manufacturer of athletic training, physical therapy, and rehabilitation products, today announced that Chief Executive Officer and Director John Krier has informed the Board of his intention to resign from the company by the end of September 2023 to pursue other professional interests. Brian Baker, the company's current Chief Operating Officer, and former President and Chief Executive Officer, has accepted the role of President of Dynatronics effective immediately and will assume the titles of President, Chief Executive

      5/18/23 8:05:00 AM ET
      $DYNT
      Medical/Dental Instruments
      Health Care

    $DYNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Dynatronics Corporation (Amendment)

      SC 13G/A - DYNATRONICS CORP (0000720875) (Subject)

      2/14/23 12:35:29 PM ET
      $DYNT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Dynatronics Corporation (Amendment)

      SC 13G/A - DYNATRONICS CORP (0000720875) (Subject)

      2/13/23 12:33:51 PM ET
      $DYNT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Dynatronics Corporation (Amendment)

      SC 13G/A - DYNATRONICS CORP (0000720875) (Subject)

      1/14/22 12:22:28 PM ET
      $DYNT
      Medical/Dental Instruments
      Health Care